These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Prospects and challenges of building a cancer vaccine targeting telomerase. Vonderheide RH Biochimie; 2008 Jan; 90(1):173-80. PubMed ID: 17716803 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer. Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM Front Immunol; 2020; 11():572172. PubMed ID: 33324397 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice. Rusakiewicz S; Dosset M; Mollier K; Souque P; Charneau P; Wain-Hobson S; Langlade-Demoyen P; Adotévi O Vaccine; 2010 Aug; 28(38):6374-81. PubMed ID: 20654669 [TBL] [Abstract][Full Text] [Related]
9. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Shaw VE; Naisbitt DJ; Costello E; Greenhalf W; Park BK; Neoptolemos JP; Middleton GW Expert Rev Vaccines; 2010 Sep; 9(9):1007-16. PubMed ID: 20822343 [TBL] [Abstract][Full Text] [Related]
10. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616 [TBL] [Abstract][Full Text] [Related]
11. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Brunsvig PF; Aamdal S; Gjertsen MK; Kvalheim G; Markowski-Grimsrud CJ; Sve I; Dyrhaug M; Trachsel S; Møller M; Eriksen JA; Gaudernack G Cancer Immunol Immunother; 2006 Dec; 55(12):1553-64. PubMed ID: 16491401 [TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies. Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388 [TBL] [Abstract][Full Text] [Related]
13. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Vonderheide RH Discov Med; 2007 Aug; 7(39):103-8. PubMed ID: 18093471 [TBL] [Abstract][Full Text] [Related]
14. Uses of telomerase peptides in anti-tumor immune therapy. Li H; Katik I; Liu JP Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818 [TBL] [Abstract][Full Text] [Related]
15. Telomerase as a universal tumor antigen for cancer vaccines. Beatty GL; Vonderheide RH Expert Rev Vaccines; 2008 Sep; 7(7):881-7. PubMed ID: 18767939 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of tumors with human telomerase reverse transcriptase immortalized human umbilical vein endothelial cells. Mu X; Sang Y; Fang C; Shao B; Yang L; Yao K; Zhao X; Gou J; Wei Y; Yi T; Wu Y; Zhao X Int J Oncol; 2015 Nov; 47(5):1901-11. PubMed ID: 26398907 [TBL] [Abstract][Full Text] [Related]
17. Myeloid dendritic cells loaded with dendritic tandem multiple antigenic telomerase reverse transcriptase (hTERT) epitope peptides: a potentially promising tumor vaccine. Niu BL; Du HM; Shen HP; Lian ZR; Li JZ; Lai X; Wei SD; Zou LQ; Gong JP Vaccine; 2012 May; 30(23):3395-404. PubMed ID: 22480929 [TBL] [Abstract][Full Text] [Related]
18. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Yan J; Pankhong P; Shin TH; Obeng-Adjei N; Morrow MP; Walters JN; Khan AS; Sardesai NY; Weiner DB Cancer Immunol Res; 2013 Sep; 1(3):179-189. PubMed ID: 24777680 [TBL] [Abstract][Full Text] [Related]
19. A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Zanetti M Nat Rev Clin Oncol; 2017 Feb; 14(2):115-128. PubMed ID: 27245281 [TBL] [Abstract][Full Text] [Related]
20. Diepitope multiple antigen peptide of hTERT trigger stronger anti-tumor immune responses in vitro. Liao ZL; Luo G; Xie X; Tang XD; Bai JY; Guo H; Yang SM Int Immunopharmacol; 2013 Aug; 16(4):444-50. PubMed ID: 23714071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]